Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...